Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

N-Methyldopamine (epinine), one of the few modifications of the dopamine (DA) molecule that retains agonist activity at the DA1 receptor, was administered orally as the diisobutyric ester, ibopamine (100, 200, and 300 mg), to 15 patients with congestive heart failure. An increase in cardiac index and decline in systemic vascular resistance was observed with each dose, and these hemodynamic effects persisted for 3 to 6 hr. Small transient increments in right atrial and pulmonary capillary wedge pressures occurred 0.5 hr after ingestion of 200 and 300 mg of ibopamine, but these pressures returned to baseline or lower levels within 30 min. Heart rate and mean arterial pressure were unchanged. Plasma concentrations of epinine peaked 0.5 hr after administration of drug and then declined to minimal levels at 3 hr. Ten patients enrolled in a trial to evaluate the efficacy of long-term therapy with ibopamine; after 8 weeks of treatment, the initial hemodynamic responses to the drug were attenuated and no significant improvement in oxygen uptake at peak exercise was observed. A decline in plasma norepinephrine concentrations, which could be attributed to activation of alpha 2-adrenoceptors and/or DA2 receptors on sympathetic nerves, was observed after initial administration of ibopamine and persisted after long-term drug ingestion; no long-term hemodynamic benefit could be ascribed to the reduction in sympathetic activity.

Absence of alpha-methyldopamine in rat striatum after chronic administration of d-amphetamine.

Direct measurement by gas chromatography methane chemical ionization mass spectrometry of alpha-methyldopamine and alpha-methylnorepinephrine in rat striatum has shown the failure of these compounds to be accumulated in vivo after chronic administration of d-amphetamine despite the accumulation of alpha-methyltyramine, an immediate in vitro precursor. Further, both alpha-methyldopamine and alpha-methyltyramine accumulate in rat striatum after administration of alpha-methyltyrosine. These data suggest that, after administration of alpha-methyltyrosine, alpha-methyldopamine is formed via decarboxylation of alpha-methyldopa and not from hydroxylation of alpha-methyltyramine. Finally, our results indicate that alpha-methyldopamine does not play a role in the development of tolerance to d-amphetamine.

[Effect of benzatropine on the O-methylation of striatal dopamine]. / Action de la benzatropine sur la O-méthylation de la dopamine striatale

After treatment by nialamid, benztropine administered to Rats produced an increase in the level of 3-O-methyldopamine in the corpus striatum. It produced a slight increase in the level of striatal dopamine and no change in the level of norepinephrine. The monoamine oxydase and catechol-O-methyltransferase activities of remaining brain showed no variations by benztropine. The results suggest the possible involvement of striatal dopamine and its extraneuronally catabolism in the antiparkinsonian effect of benztropine.

Lack of epinine formation in adrenal medulla and brain of rats during cold exposure and inhibition of dopamine beta-hydroxylase.

Cold exposure of rats for 4 h and simultaneous inhibition of dopamine beta-hydroxylase by FLA-63 (25mg/kg) led to a reduction of the catecholamine content of the adrenal medulla by 46% and of the brain by 68%. Additional injections of 5 mg/kg FLA-63 4 and 9 h after beginning of the experiments, respectively, kept the catecholamine content on this low level (brain) or decreased it further (adrenal medulla). Administration of 5 mg/kg (-)DOPA together with the mono-amine oxidase inhibitor pargyline (50 mg/kg) 24 h after the first injection of FLA-63 stimulated the resynthesis. It amounted for the adrenal medulla to 20 mug/kg body weight/8 h and for the brain to 45ng/g tissue wet weight/8 h. Paper chromatographic analyses of the extracts of adrenal medulla and brain, respectively, performed at each time of the different injections, clearly identified adrenaline, noradrenaline and dopamine (in traces) in the adrenal medulla as well as noradrenaline and dopamine in the brain; epinine on the contray could not be demonstrated, not even in traces. Since at least 25 ng of epinine can be detected with certainty by our method, it can be concluded that epinine is not formed in amounts greater than 75 ng/pair adrenal glands or 37.5 ng/brain. The present results support the view that the main pathway of adrenaline biosynthesis in the suprarenal medulla and the brain proceeds via noradrenaline and not via epinine.